Cadrenal Therapeutics to Present at Emerging Growth Conference June 12, 2024

On June 11, 2024, Cadrenal Therapeutics, Inc., a biopharmaceutical company listed on Nasdaq under the ticker CVKD, announced its participation in the Emerging Growth Conference. Cadrenal Therapeutics is known for developing tecarfarin, an advanced Vitamin K Antagonist (VKA) used as an oral and reversible anticoagulant. This medication aims to prevent heart attacks, strokes, and deaths caused by blood clots in patients with rare cardiovascular conditions.

Cadrenal's management team is scheduled to deliver a webcasted presentation at the Conference, which will take place on June 12, 2024, at 10:50 am ET. Following the presentation, there will be a session for questions from the audience. Those interested in viewing the presentation can find the webcast link on the investor relations page of Cadrenal's website.

For individuals who cannot attend the live event, an archived version of the webcast will be available on Cadrenal's website and the Emerging Growth YouTube Channel. Additionally, Cadrenal's management will be available for one-on-one meetings with investors after the Conference. Interested parties can request a virtual one-on-one meeting by contacting their Emerging Growth Conference representative or by emailing the investor relations team at Cadrenal.

Cadrenal Therapeutics is focused on addressing unmet needs in anticoagulation therapy through the development of tecarfarin. Tecarfarin is a next-generation VKA designed to prevent blood clots, heart attacks, and strokes in patients who require lifelong anticoagulation. The drug has received orphan drug designation from the FDA for preventing thrombosis and thromboembolism in patients with implanted mechanical circulatory support devices, such as the left ventricular assist device (LVAD). Additionally, tecarfarin has orphan drug and fast-track designations for preventing systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).

Tecarfarin is notable for its unique metabolism pathway, which differentiates it from warfarin, the most commonly prescribed VKA. The drug has been evaluated in eleven human clinical trials involving over 1,000 participants, including healthy adult subjects and patients with chronic kidney disease. It has generally been well-tolerated throughout Phase 1, Phase 2, and Phase 2/3 clinical trials.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!